Association of anxiety and depressive symptoms with anthropometric and laboratory markers in patients with autoimmune disorders of the joints and connective tissue
Suggested citation:
Rukavishnikov GV, Smirnova AA, Kas'yanov ED, et al. [Association of anxiety and depressive symptoms with anthropometric and laboratory markers in patients with autoimmune disorders of the joints and connective tissue]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2022;(6):26-32. Russian
In a cross-sectional study 131 patients with various forms of joint disease were evaluated to analyze the prevalence and level of anxiety and depression in autoimmune variants of joint and connective tissue disorders. Two samples were formed: the first included patients with autoimmune disorders of the rheumatological category, 51 patients; the second – patients with non-inflammatory disorders of the connective tissue and joints, 80 patients. The evaluation of anthropometric indicators included the assessment of height, weight and the calculation of the body mass index based on the Ketle’s formula. ESR, CRP were assessed in the laboratory studies. All study participants were evaluated with a psychometric examination with the use the Hospital Anxiety and Depression Scale (HADS). Symptoms of depression were significantly more prevalent in patients with connective tissue disorders compared with the group of patients with non-inflammatory disorders (18.8%, p=0.033). The main factors associated with higher severity of depressive symptoms were older age and increased BMI. At the same time, nonspecific inflammatory markers (ESR, CRP) did not differ significantly in patients with comorbid AID and affective disorders and in the group with AID without them.
Keywords anxiety; depression; autoimmune joint disorders; degenerative joint disorders; psychometric screening
1. World Health Organization, Depression, 2022. URL: https://www.who.int/news-room/fact-sheets/detail/depression (assessed on: 10.09.2022). 2. Sambamoorthi U, Shah D, Zhao X. Healthcare burden of depression in adults with arthritis. Expert Rev Pharmacoecon Outcomes Res. 2017;17(1):53–65. DOI: https://doi.org/10.1080/14737167.2017.1281744 3. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851–8. DOI: https://doi.org/10.1016/S0140-6736(07)61415-9 4. Ozcetin A, Ataoglu S, Kocer E, et al. Effects of depression and anxiety on quality of life of patients with rheumatoid arthritis, knee osteoarthritis and fibromyalgia syndrome. West Indian Med J. 2007;56(2):122–9. DOI: https://doi.org/10.1590/s0043-31442007000200004 5. Mazo GE, Dubinina EE, Krizhanovskii AS. [Inflammation and depression: the role of oxidative stress, hormonal and cellular factors]. Zh Nevrol Psikhiatr Im SS Korsakova. 2014;114(1):80–4. (In Russ.) 6. Rukavishnikov GV, Mazurov VI, Neznanov NG, et al. Rheumatoid arthritis and depression: shared pathological mechanisms. Clinical Medicine. 2019;97(8–9):586–91. (In Russ.) DOI: https://doi.org/10.34651/0023-2149-2019-97-8-9-586-59 7. Rukavishnikov GV, Smirnova AA, Neznanov NG, et al. Shared pathological mechanisms of systemic lupus erythematosus and affective disorders. Herald of North-Western State Medical University named after II Mechnikov. 2021;13(2):5–14. (In Russ.) DOI: https://doi.org/10.17816/mechnikov61262 8. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24–31. DOI: https://doi.org/10.1016/j.it.2005.11.00 9. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86. DOI: https://doi.org/10.1097/PSY.0b013e3181907c1b 10. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57. DOI: https://doi.org/10.1016/j.biopsych.2009.09.033 11. Haapakoski R, Mathieu J, Ebmeier KP, et al. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–15. DOI: https://doi.org/10.1016/j.bbi.2015.06.001 12. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–709. DOI: https://doi.org/10.1038/mp.2016 13. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381–91. DOI: https://doi.org/10.1001/jamapsychiatry.2014.1611 14. Nerurkar L, Siebert S, McInnes IB, Cavanagh J. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry. 2019;6(2):164–73. DOI: https://doi.org/10.1016/S2215-0366(18)30255-4 15. Zigmond AS, Snaith RP. The Hospital Anxiety And Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–70. DOI: https://doi.org/10.1111/j.1600-0447.1983.tb09716.x 16. Pryce CR, Fontana A. Depression in Autoimmune Diseases. Curr Top Behav Neurosci. 2017;31:139–54. DOI: https://doi.org/10.1007/7854_2016_7 17. Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24(1):18–33. DOI: https://doi.org/10.1038/s41380-018-0017-5 18. Troubat R, Barone P, Leman S, et al. Neuroinflammation and depression: A review. Eur J Neurosci. 2021;53(1):151–71. DOI: https://doi.org/10.1111/ejn.14720
DOI: http://dx.doi.org/10.47877/1560-957Х-2022-10603
Article Metrics
Metrics powered by PLOS ALM